

2025 KNOWLEDGE-BASED HOME-STUDY CE FOR PHARMACISTS AND PHARMACY TECHNICIANS

DON'T GET LOST IN THE ALPHABET SOUP: OVERVIEW OF EMERGING CANCER IMMUNE THERAPIES

Speaker: Genevieve Kumapley, PharmD, BCOP, Clinical Pharmacy Manager, Holy Name Medical Center, Teaneck, NJ

Pharmacist and Pharmacy Technician Learning Objectives

Upon completion of this knowledge-based CE activity, the participant will be able to do the following:

- Describe the new classes of immune-oncology therapies, including their mechanisms of action, indications for use and adverse effects.
- Summarize the evidence for new chimeric antigen receptor T-cell therapies, bispecific T-cell engagers and antibody drug conjugates
- Review the management of antibody conjugate and other immune-related adverse effects

Accreditation Information:

ACPE UAN: 0122-0000-25-077-H01-P/T

CPE Credit Hours: 1.0 hours (0.1 CEU) of CE credit

Release Date: November 3, 2025

Expiration Date: November 3, 2028

Disclosure: Dr. Kumapley, the moderators and the planners for this activity have no relevant financial relationship(s) with ineligible companies to disclose.

Sponsorship: This program is conducted solely by Premier and has no commercial or non-commercial support or sponsorship.

To participate and obtain CE credit, participants must complete the following steps:

1. Log on to Premier's [CE website](#) to register for the activity under "Home Study CE"
2. View and listen to the recorded activity
3. Complete both the post-test learning assessment questions and the activity evaluation within 45 days of the event.

[Click here](#) to view CE webinar system requirements for the learner to complete the online activity, including the internet browser(s) supported and minimum versions of each, and the minimum memory, storage, processor, and internet.

Note: CPE participation will be provided to CPE Monitor if the participant attains a passing grade of 70% or better on the post-test learning assessment questions. NABP e-profile ID number and birthdate (MMDD) must be provided by participants to receive CE credit.



Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This CE activity is provided as a free, value-added service to Premier health- system pharmacy staff.

For any questions regarding the CE activity, please contact [Premier's Pharmacy Team](#).

2025 KNOWLEDGE-BASED HOME-STUDY CE FOR PHARMACISTS AND PHARMACY TECHNICIANS

Don't Get Lost in the Alphabet Soup: Overview of Emerging Cancer Immune Therapies

Genevieve Kumapley, PharmD, BCOP

Clinical Pharmacy Manager

Holy Name Medical Center

Teaneck, NJ

ACPE UAN: 0122-0000-25-077-H01-P/T

CPE Credit Hours: 1.0 hour (0.1 CEU)

PHARMACIST & PHARMACY TECHNICIAN LEARNING OBJECTIVES

Upon completion of this CE activity, the participant will be able to do the following:

- Describe the new classes of immune-oncology therapies, including their mechanisms of action, indications for use and adverse effects.
- Summarize the evidence for new chimeric antigen receptor T-cell therapies, bispecific T-cell engagers and antibody drug conjugates
- Review the management of antibody conjugate and other immune-related adverse effects.

Speaker Bio:

Dr. Genevieve Kumapley is a Clinical Pharmacy Manager and PGY-1 Residency Program Director at Holy Name Medical Center. She received her Doctor of Pharmacy Degree with Honors from the University of Illinois at Chicago. Dr. Kumapley is a Board-Certified Oncology Pharmacist with over 25 years of experience. She also holds an Adjunct Clinical Professor appointment with Rutgers University Ernest Mario School of Pharmacy & Fairleigh Dickinson University School of Pharmacy and Health Sciences. Dr. Kumapley is also the founder of MyGOAL Inc, a 501 c(3) non-profit organization that serves individuals with Autism and other Intellectual disabilities.

Dr. Kumapley, the moderators and the planners for this activity have no relevant financial relationship(s) with ineligible companies to disclose.